Minimally invasive robot-B (02252) is now up more than 4%. As of press release, it has risen 4.02% to HK$17.06, with a turnover of HK$11.896 million.
The Zhitong Finance App learned that minimally invasive robot-B (02252) has now risen by more than 4%. As of press release, it has risen 4.02% to HK$17.06, with a turnover of HK$11.896 million.
According to the news, minimally invasive robotics was recently announced, and the R-ONE vascular intervention robot introduced in a joint venture established by the company and France's Robocath S.A.S in China has been approved for marketing by the State Drug Administration. In addition, the minimally invasive robotics flagship four-arm endoscopic surgery robot has recently won multiple bids.
CITIC Construction Investment pointed out that looking ahead to Q4 and 2024, with the gradual recovery of hospital outpatient surgeries, rapid rollout of innovative device products, and some companies are expected to gradually reverse losses, we believe that investment sentiment in Hong Kong stock devices should gradually become more optimistic. In choosing investment targets, it is recommended to choose long-term players with excellent fundamentals and good liquidity. Among them, a new batch of surgical robot configuration plans have been released, and minimally invasive robots are expected to seize policy opportunities and be rapidly deployed.